XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.24.3

Balance Sheet Components | 9 Months Ended
--- | ---
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Balance Sheet Components | Balance Sheet Components Prepaid and other current assets Prepaid and other current assets consist of the following (in thousands):
| September 30, 2024 |  | December 31, 2023
Prepaid general and administration | $ | 1,397 |  |  | $ | 1,033 |
Prepaid research and development | 4,870 |  |  | 300 |
Other receivable | 2,915 |  |  | 3,643 |
Prepaid contract research organization expenses | 443 |  |  | 1,322 |
Other current assets | 1,958 |  |  | 2,604 |
Total prepaid and other current assets | $ | 11,583 |  |  | $ | 8,902 |
Property, Plant and Equipment, Net Property, plant and equipment, net consist of the following (in thousands):
| September 30, 2024 |  | December 31, 2023
Land | $ | 31,243 |  |  | $ | 31,243 |
Laboratory equipment | — |  |  | 8,291 |
Buildings | 102,433 |  |  | 102,433 |
Office and computer equipment | 509 |  |  | 831 |
Leasehold improvements | — |  |  | 1,424 |
Manufacturing equipment | — |  |  | 2,017 |
Total property, plant and equipment, gross | 134,185 |  |  | 146,239 |
Less: accumulated depreciation | (4,038) |  |  | (7,555) |
Total property, plant and equipment, net | $ | 130,147 |  |  | $ | 138,684 |
Depreciation expense was $0.9 million and $1.0 million for the three months ended September 30, 2024 and 2023, respectively, and was $2.9 million and $3.7 million for the nine months ended September 30, 2024 and 2023, respectively, in the condensed consolidated statements of operations and comprehensive loss. The Company capitalized interest of nil during the three months ended September 30, 2024 and 2023, while during the nine months ended September 30, 2024 and 2023, the Company capitalized nil and $2.4 million, respectively, of interest related to qualifying expenditures for construction work-in-progress for its Tarzana manufacturing facility. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands):
| September 30, 2024 |  | December 31, 2023
Accrued compensation and benefits | $ | 2,401 |  |  | $ | 1,026 |
Accrued operational expenses | 957 |  |  | 1,412 |
Accrued restructuring costs | 3,453 |  |  | 3,136 |
Accrued research, development and clinical trial expenses | 406 |  |  | 1,833 |
Operating lease liabilities, current | 1,761 |  |  | 1,750 |
Other current liabilities | 107 |  |  | 190 |
Total accrued expenses and other current liabilities | $ | 9,085 |  |  | $ | 9,347 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration